|
市場調查報告書
Toll樣受體(TLR)激動劑及拮抗劑市場競爭分析
Competitor Analysis: Toll-Like Receptor (TLR) Agonists & Antagonists
|
Toll樣受體(TLR)激動劑及拮抗劑市場競爭分析 是由出版商La Merie Publishing在2011年10月所出版的。
這份英文市場調查報告書包含152 Pages 價格從美金800起跳。
本報告提供癌症和感染病，敗血症，為了過敏的治療和預防，把Toll樣受體(TLR)作為標靶的小分子，蛋白質，DNA，RNA，疫苗的開發平台相關分析，受體激動劑及拮抗劑，佐劑，及疫苗的研究開發現況和今後的預測彙整，為您概述為以下內容。
第1章 Toll樣受體激動劑:受體各類型
- TLR2受體激動劑
- TLR3受體激動劑
- TLR4受體激動劑
- TLR7受體激動劑
- TLR7/8受體激動劑
- TLR8受體激動劑
- TLR9受體激動劑
- 非特定TLR受體激動劑
第2章 Toll樣受體激動劑:各治療領域
- 皮膚類疾病
- 腸胃系統疾病
- 感染症·病毒
- 神經科·精神科
- 癌症
- 肺部疾病·呼吸系統疾病
- 風濕·自體免疫疾病
第3章 Toll樣受體拮抗劑:受體各類型
- TLR2拮抗劑
- TLR3拮抗劑
- TLR4拮抗劑
- TLR7/8/9拮抗劑
第4章 Toll樣受體拮抗劑:各治療領域
- 心血管疾病·急救
- 腸胃系統疾病
- 風濕·自體免疫疾病
第5章 Toll樣受體佐劑:受體各類型
- TLR3佐劑
- TLR2/4佐劑
- TLR4佐劑
- TLR7/8/9佐劑
- TLR9佐劑
- TLR佐劑:非特定
第6章 Toll樣受體佐劑疫苗:受體各類型
- TLR3受體激動劑的佐劑疫苗
- TLR4受體激動劑的佐劑疫苗
- TLR5受體激動劑的佐劑疫苗
- TLR9受體激動劑的佐劑疫苗
- 非特定TLR受體激動劑的佐劑疫苗
第7章 Toll樣受體佐劑疫苗:各治療領域
- 感染疾病的預防用TLR佐劑疫苗
- 癌症的治療用TLR3-佐劑疫苗
- 癌症的治療用TLR4-佐劑疫苗
- 肺部疾病·呼吸系統疾病的治療用TLR4-佐劑疫苗
- 感染疾病的治療用TLR9-佐劑疫苗
- 癌症的治療用TLR9-佐劑疫苗
- 神經·精神科的治療用TLR9-佐劑疫苗
- 癌症的治療用非特定TLR佐劑疫苗
- 感染疾病的治療用非特定TLR佐劑疫苗
Abstract
Product description
The Competitive Intelligence Report Toll-Like Receptor (TLR) Agonists &
Antagonists provides a competitor analysis in the development pipeline of
novel small molecules, proteins, DNA, RNA and vaccines targeting the toll-like
receptors (TLR) for treatment or prevention of cancer, infectious diseases,
sepsis and allergy as of October 2011. Purchase of the downloadable pdf report
includes a 6-month online access to the data of the report and any updates
since the publication date. Credentials to access the database will be sent by
e-mail and allow online work with the project data to print or export an
individual report.
Toll-like receptors (TLRs) are a class of proteins that play a key role in the
innate immune system. TLRs have become attractive targets for activation or
antagonism in pharmaceutical research. TLR agonists find use either alone or
as adjuvants in combination with vaccine antigens. TLR antagonists are also
under development for diseases with overwhelming immune response. Special
attention has focused on the role of TLR agonists as novel adjuvants in
prophylactic and therapeutic vaccines. They enhance dendritic cell function
and their ability to prime T cells. Agonists that target toll-like receptors
are being used clinically either alone or in combination with tumor antigens
and showing initial success both in terms of enhancing immune responses and
eliciting antitumor activity. TLR agonists and adjuvants are being
investigated in a number of other therapeutic areas, such as in allergy, skin
or infectious diseases.
The report includes a compilation of currently active projects in research and
development of TLR agonists, antagonists, adjuvants and TLR-adjuvanted
vaccines. In addition, the report lists company-specific R&D pipelines of TLR
agonists and antagonists. Competitor projects are listed in a tabular format
providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Therapeutic Area,
- Product Category
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information
about the pipeline of R&D projects for targets, diseases, technologies and
companies at low prices. The information is provided in a tabular format and
fully referenced.
Table of Contents
1. TLR Agonists - by Receptor Subtype
- TLR3 Agonists
- TLR4 Agonists
- TLR7 Agonists
- TLR7/8 Agonists
- TLR8 Agonists
- TLR9 Agonists
- TLR Agonists unispecified
2. TLR Agonists - by Therapeutic Area
- Dermatology
- Gastrointestinal
- Infectious & toxicology
- Neurology & psychiatry
- Oncology
- Pulmonary & respiratory
- Rheumatoid & autoimmune
3. TLR Antagonists - by Receptor Subtype
- TLR2 Antagonists
- TLR3 Antagonists
- TLR4 Antagonists
- TLR7/(8)/9 Antagonists
4. TLR Antagonists - by Therapeutic Area
- Cardiovascula & acute care
- Dermatology
- Rheumatoid & autoimmune
5. TLR Adjuvants by Receptor Subtype
- TLR3 Adjuvants
- TLR2/4 Adjuvants
- TLR4 Adjuvants
- TLR7/8/9 Adjuvants
- TLR9 Adjuvants
- TLR Adjuvants - unspecified
6. TLR - Adjuvanted Vaccines - by Receptor Subtype
- Vaccines adjuvanted with TLR3 agonist
- Vaccines adjuvanted with TLR4 agonist
- Vaccines adjuvanted with TLR5 agonist
- Vaccines adjuvanted with TLR9 agonist
- Vaccines adjuvanted with unspecified TLR agonist
7. TLR - Adjuvanted Vaccines - by Therapeutic Area
- Prophylactic TLR-Adjuvanted Vaccines in Infectious Diseases
- Therapeutic TLR3-Adjuvanted Vaccines in Oncology
- Therapeutic TLR4-Adjuvanted Vaccines in Oncology
- Therapeutic TLR4-Adjuvanted Vaccines in Pulmonary & Respiratory Diseases
- Therapeutic TLR9-Adjuvanted Vaccines in Infectious Diseases
- Therapeutic TLR9-Adjuvanted Vaccines in Oncology
- Therapeutic TLR9-Adjuvanted Vaccines in Neurology & psychiatry
- Therapeutic unspecified TLR-Adjuvanted Vaccines in Oncology
- Therapeutic unspecified TLR-Adjuvanted Vaccines in Infectious Diseases
|
